

**510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION  
DECISION SUMMARY  
ASSAY ONLY TEMPLATE**

**A. 510(k) Number:**

k050400

**B. Purpose for Submission:**

Addition of cephalothin to the BD Phoenix™ Automated Microbiology System

**C. Measurand:**

Cephalothin 0.5 - 64 µg/ml

**D. Type of Test:**

Antimicrobial Susceptibility Test (AST) (Quantitative and Qualitative) colorimetric oxidation-reduction, growth-based

**E. Applicant:**

Becton, Dickinson & Company

**F. Proprietary and Established Names:**

BD Phoenix™ Automated Microbiology System – Cephalothin Gram Positive Panel

**G. Regulatory Information:**

1. Regulation section:  
21 CFR 866.1645 Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System
2. Classification:  
II
3. Product code:  
LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
4. Panel:  
83 Microbiology

**H. Intended Use:**

1. Intended use(s):  
The BD Phoenix™ Automated Microbiology System is intended for *in vitro* quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of gram-negative aerobic and facultative anaerobic bacteria belonging to the family *Enterobacteriaceae* and non – *Enterobacteriaceae* and most gram-positive bacteria isolates from pure culture belonging to the genera *Staphylococcus* and *Enterococcus*.

The BD Phoenix™ Automated Microbiology System is intended for the *in vitro* rapid identification (ID) and quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of gram-positive aerobic and facultative anaerobic bacteria belonging to the genera *Staphylococcus* and *Enterococcus*.

2. Indication(s) for use:

This submission is for the addition of the antibiotic cephalothin at concentrations of 0.5 – 64 µg/mL to the gram positive susceptibility panel for testing *Staphylococcus* spp.

3. Special conditions for use statement(s):

For prescription use only

4. Special instrument requirements:

Not Applicable

## **I. Device Description:**

The BD Phoenix™ Automated Microbiology System includes instrumentation and software, sealed and self-inoculating molded polystyrene trays with 136 micro-wells containing dried reagents, and specific inoculum broth formulations for ID and AST Indicator. The organism to be tested must be a pure culture and be preliminarily identified as gram positive or gram negative. Colonies are then suspended in broth, and equated to a 0.5 McFarland with the recommendation to use the BD CrystalSpec™ Nephelometer. A further dilution is made into an AST broth, which contains an AST indicator, prior to inoculating the panel. The AST broth is a cation-adjusted formulation of Mueller-Hinton broth containing 0.01% Tween 80. After adding the indicator solution to the AST inoculum the color is blue and after inoculation and incubation goes to pink to colorless as reduction in the panel well proceeds. Inoculated panels are barcode scanned and loaded into the BD Phoenix™ Automated Microbiology System instrument where the panels are continuously incubated at 35°C. The AST has a final inoculum of  $5 \times 10^5$  CFU/ml. The instrument incubates, reads and records the results of the biochemical substrates and antimicrobial agents and interprets the reactions to give an ID of the isolate and MIC value and category interpretation of the antimicrobial agents. Organisms growing in the presence of a given antimicrobial agent reduce the indicator, signaling organism growth and resistance to the antimicrobial agent. Organisms killed or inhibited by a given antimicrobial do not cause reduction of the indicator and therefore do not produce a color change. Additional interpretation is done using software driven “EXPERT” System using rules derived from the Clinical and Laboratory Standards Institute (CLSI).

Readings are taken every 20 minutes with an ID result available between 2-12 hours and an AST result available between 4-16 hours. This is only an autoread result; there are no manual readings possible.

**J. Substantial Equivalence Information:**

1. Predicate device name(s):  
VITEK® System
2. Predicate 510(k) number(s):  
N50510
3. Comparison with predicate:

Similarities		
Item	Device	Predicate
1.	Isolated colonies from culture used	Isolated colonies from culture used
2.	Report results as minimum inhibitory concentration (MIC) and categorical interpretation (SIR)	Report results as minimum inhibitory concentration (MIC) and categorical interpretation (SIR)
3.	<16 hours	<16 hours

Differences		
Item	Device	Predicate
1.	Results are determined from serial twofold dilutions of antimicrobial agents	Results are determined from extrapolation of doubling dilutions
2.	Inoculum density equated to 0.5 McFarland standard	Inoculum density equated to 1.0 McFarland standard
3.	Automated growth based enhanced by use of a redox indicator (colorimetric oxidation-reduction) to detect organism growth.	Automated growth based with detection using an attenuation of light measured by an optical scanner.

**K. Standard/Guidance Document Referenced (if applicable):**

“Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test Systems; Guidance for Industry and FDA”; CLSI M7 (M100-S15) “Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard.”

**L. Test Principle:**

The system employs conventional, colorimetric, fluorogenic and chromogenic

substrates to identify the genus and species of the isolate. The AST portion of the BD Phoenix™ Automated Microbiology System is a broth based microdilution method that utilizes a redox indicator (colorimetric oxidation-reduction) to enhance detection of organism growth. The MIC is determined by comparing growth in wells containing serial two-fold dilutions of an antibiotic to the growth in “growth control wells” which contains no antibiotic.

#### M. Performance Characteristics (if/when applicable):

##### 1. Analytical performance:

###### a. *Precision/Reproducibility:*

Eleven gram-positive on-scale organisms were evaluated for site to site and inter site reproducibility demonstrating >95% reproducibility. The ten isolate study described in the guidance document was used (10 organisms tested 3 times on 3 days at 3 sites).

###### b. *Linearity/assay reportable range:*

Not applicable

###### c. *Traceability, Stability, Expected values (controls, calibrators, or methods):*

The CLSI recommended QC isolate, *S. aureus* ATCC 29213 was tested on every test occasion with the reference method and the BD Phoenix™. Since the expected range of this isolate was off-scale, another QC strain, *E. faecalis* ATCC 51299 with on scale results was used. The reference method QC results were in range for every day tested. The Phoenix™ was tested a sufficient number of times to demonstrate that the system can produce QC results in the CLSI recommended ranges most of the time. Both QC organisms had the same mode with the reference and the BD Phoenix™.

Quality Control Table

<b>ORGANISM</b>	<b>Conc.</b>	<b>Reference</b>			<b>Phoenix</b>		
<i>E. faecalis</i>	1				1		
ATCC 51299	8				1		
Expected Range:	16	2					
16 – 64 µg/mL	32	217			229		
	64	29			12		
	>64				1		
<i>S. aureus</i>	≤0.5	251			249		
ATCC 29213	1	1					
Expected Range:	32				1		
≤0.5 µg/mL							

Inoculum density control: The organism suspension density of the ID broth was equivalent to a 0.5 McFarland standard using the BBL™ CrystalSpec™ Nephelometer which was verified each day of testing. Internal data was used to demonstrate that the use of the BBL™ CrystalSpec™ Nephelometer would produce reproducible results. Five different instruments were used.

- d. *Detection limit:*  
Not Applicable
- e. *Analytical specificity:*  
Not Applicable
- f. *Assay cut-off:*  
Not Applicable

## 2. Comparison studies:

### a. *Method comparison with predicate device:*

The CLSI recommended broth dilution reference panel was prepared according to the CLSI recommendation. Clinical testing was performed at four sites. The testing included both fresh clinical isolates and stock isolates along with a challenge set with known results. Since Oxacillin Resistant isolates will be reported as Resistant, only Oxacillin Sensitive isolates were evaluated. The test device had a growth rate of >90%. A comparison was provided to the reference method with the following agreement.

Summary Table for *Stapylococcus spp. (Methicillin Susceptible only)*

	EA Tot	EA N	EA %	Eval EA Tot	Eval EA N	Eval EA %	CA N	CA %	#R	min	maj	vmj
<b>Clinical</b>	<b>857</b>	<b>826</b>	<b>96.4</b>	<b>142</b>	<b>112</b>	<b>78.9</b>	<b>841</b>	<b>98.1</b>	<b>15</b>	<b>10</b>	<b>6</b>	<b>0</b>
<b>Challenge</b>	<b>47</b>	<b>44</b>	<b>93.6</b>	<b>9</b>	<b>6</b>	<b>66.7</b>	<b>45</b>	<b>95.7</b>	<b>6</b>	<b>0</b>	<b>2</b>	<b>0</b>
<b>Combined</b>	<b>904</b>	<b>870</b>	<b>96.2</b>	<b>151</b>	<b>118</b>	<b>78.1</b>	<b>886</b>	<b>98</b>	<b>21</b>	<b>10</b>	<b>8</b>	<b>0</b>

**EA**-Essential Agreement

**CA**-Category Agreement

**R**-resistant isolates

**maj**-major discrepancies

**vmj**-very major discrepancies

**min**- minor discrepancies

Essential agreement (EA) is when the BD Phoenix™ panels agree with the reference test panel results exactly or within one doubling dilution of the reference method. Category agreement (CA) is when the BD Phoenix™ panel result interpretation agrees exactly with the reference panel result interpretation.

There are no vmj errors for this study. The maj error rate of 0.9% and min error rate of 1.1% are both acceptable.

- b. *Matrix comparison:*  
Not Applicable

3. Clinical studies:

a. *Clinical Sensitivity:*

Not Applicable

b. *Clinical specificity:*

Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable):

Not Applicable

4. Clinical cut-off:

Not Applicable

5. Expected values/Reference range:

*Staphylococcus spp.*  $\leq 8$  (S), 16 (I),  $\geq 32$  (R)

The Interpretative criteria, QC isolates and the expected ranges are the same as recommended by CLSI. All values will be included in the package insert.

**N. Proposed Labeling:**

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

**O. Conclusion:**

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.